ASCO 2019

CytImmune is excited to announce that our collaborative work with the US National Cancer Institute has resulted in an ASCO abstract. ASCO Submission Category Developmental Therapeutics and Tumor Biology (Nonimmuno), New Targets and New Technologies Authors and Institutions Naris Nilubol, Surgical Oncology Program, National Cancer Institute, NIH, Bethesda, MD 208921 David Oarr and Lawrence Tamarkin, …